170 related articles for article (PubMed ID: 36323745)
1. RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma.
Hiratsuka T; Yamamoto T; Yoshizawa A; Toyokuni S; Tsuruyama T
Sci Rep; 2022 Nov; 12(1):18519. PubMed ID: 36323745
[TBL] [Abstract][Full Text] [Related]
2. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
[TBL] [Abstract][Full Text] [Related]
3. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
4. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
5. SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.
Nakagiri T; Amatya VJ; Kushitani K; Kambara T; Aoe K; Endo I; Miyata Y; Okada M; Takeshima Y
Am J Surg Pathol; 2024 Feb; 48(2):140-149. PubMed ID: 37899530
[TBL] [Abstract][Full Text] [Related]
6. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
Amatya VJ; Kushitani K; Kai Y; Suzuki R; Miyata Y; Okada M; Takeshima Y
Mod Pathol; 2018 May; 31(5):809-815. PubMed ID: 29327712
[TBL] [Abstract][Full Text] [Related]
7. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
[TBL] [Abstract][Full Text] [Related]
8. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
9. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.
Sahin N; Akatli AN; Celik MR; Ulutas H; Samdanci ET; Colak C
Pathol Oncol Res; 2017 Jul; 23(3):487-491. PubMed ID: 27761727
[TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
11. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma.
Kushitani K; Amatya VJ; Okada Y; Katayama Y; Mawas AS; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y
Histopathology; 2017 Feb; 70(3):375-384. PubMed ID: 27589012
[TBL] [Abstract][Full Text] [Related]
12. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
Naso JR; Tsuji S; Churg A
Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
[TBL] [Abstract][Full Text] [Related]
13. Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.
Sejben A; Pancsa T; Tiszlavicz L; Furák J; Paróczai D; Zombori T
Thorac Cancer; 2023 Apr; 14(10):857-863. PubMed ID: 36808895
[TBL] [Abstract][Full Text] [Related]
14. SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma.
Kambara T; Amatya VJ; Kushitani K; Suzuki R; Fujii Y; Kai Y; Miyata Y; Okada M; Takeshima Y
Am J Surg Pathol; 2020 Sep; 44(9):1259-1265. PubMed ID: 32496433
[TBL] [Abstract][Full Text] [Related]
15. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
16. Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases.
Churg A; Naso JR
Histopathology; 2023 Feb; 82(3):385-392. PubMed ID: 36008876
[TBL] [Abstract][Full Text] [Related]
17. Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma.
Naso JR; Cheung S; Ionescu DN; Churg A
Am J Surg Pathol; 2021 Sep; 45(9):1245-1251. PubMed ID: 33782226
[TBL] [Abstract][Full Text] [Related]
18. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
19. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
[TBL] [Abstract][Full Text] [Related]
20. Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma.
van Pel DM; Cheung S; Ionescu DN; Churg A
Hum Pathol; 2023 Nov; 141():64-68. PubMed ID: 37776956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]